Clinical Trial

Database Linkage Study to Evaluate the Risk of Medullary Thyroid Carcinoma

Enrolling by Invitation
View on ClinicalTrials.gov →
Summary
This is a database linkage study utilizing real-world data (RWD) to determine whether certain medicines used to treat type 2 diabetes (T2D) and support weight management (called GLP-1 RAs (Glucagon-like peptide-1 receptor agonists )) are linked to an increased risk of a rare cancer called medullary thyroid carcinoma (MTC). The purpose of this study is to compare how often medullary thyroid cancer occurs in people taking these medicines versus those taking other similar treatments. This study will use dispensed prescription claims and State Cancer Registry data to assess the risk of MTC.
Trial Details
NCT Number NCT07713901
Lead Sponsor Novo Nordisk A/S
Conditions Medullary Thyroid Carcinoma
Enrollment 93,600,000 participants
Start Date 2025-12-31
Primary Completion 2026-12-31 (estimated)
Study Completion 2026-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-07-20